

Substitute for form 1449A/B/PTO¹**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	Unassigned
Filing Date	August 19, 2006/505239
First Named Inventor	TARASOVA et al.
Group Art Unit	Unassigned-1654
Examiner Name	Unassigned-HEMANT KHANNA
Attorney Docket Number	229694

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
/H.K./	AA	5,342,947		Lackey et al.	Aug. 30, 1994	
↓	AB	5,416,064		Chari et al.	May 16, 1995	
↓	AC	5,831,002		Haupt et al.	Nov. 3, 1998	
↓	AD	6,184,374	B1	Schally et al.	Feb. 6, 2001	
/H.K./	AE	6,214,865	B1	Littlefield et al.	Apr. 10, 2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
/H.K./	AF	WO	02/16368	A1	Immunogen, Inc.	Feb. 28, 2002		
/H.K./	AG	WO	99/32509		University of British Columbia	Jul. 1, 1999		

OTHER - NON PATENT LITERATURE DOCUMENTS								
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					Translation	
							Yes	No**
/H.K./	AH	AUGELLI-SZAFRAN et al., <i>Bioorg. Med. Chem.</i> , 4(10), 1733-1745 (1996)						
↓	AI	CARPENTER, <i>Curr. Opin. Cell Biol.</i> , 5, 261-264 (1993)						
↓	AJ	CHEN et al., <i>Gene Ther.</i> , 2, 116-123 (1995)						
↓	AK	CZERWINSKI et al., <i>PNAS</i> , 95, 11520-11525 (1998)						
↓	AL	DUBOWCHIK et al., <i>Pharmac. and Ther.</i> , 83, 67-123 (1999)						
↓	AM	HUANG et al., <i>Curr. Op. Genet. Dev.</i> , 11, 104-110 (2001)						
↓	AN	KIHARA et al., <i>Cancer Res.</i> , 55, 71-77 (1995)						
↓	AO	LAM et al., <i>J. Antibiot.</i> , 48(12), 1497-1501 (1995)						
↓	AP	LEMAISTRE et al., <i>Breast Cancer Res. Treat.</i> , 32, 97-103 (1994)						
↓	AQ	LING, <i>Cancer Chemother. Pharmacol.</i> , 40, S3-S8 (1997)						
↓	AR	MITCHELL et al., <i>Tetrahed. Lett.</i> , 43, 493-497 (2002)						
↓	AS	PASTAN, <i>Biochim. Biophys. Acta</i> , 1333, C1-C6 (1997)						
↓	AT	RINK et al., <i>PNAS</i> , 93, 15063-15068 (1996)						
↓	AU	ROTH et al., <i>Anticancer Drug Des.</i> , 10, 655-666 (1995)						
↓	AV	SCHALLY et al., <i>Eur. J. Endocrin.</i> , 141, 1-14 (1999)						
↓	AW	STROM et al., <i>Annu. Rev. Med.</i> , 44, 343-353 (1993)						
↓	AX	TARASOVA et al., <i>J Biol. Chem.</i> , 272(23), 14817-14824 (1997)						
↓	AY	TOSHIMA et al., <i>Angew. Chem. Int. Ed.</i> , 39(20), 3656-3658 (2000)						
↓	AZ	TROUET et al., <i>PNAS</i> , 79, 626-629 (1982)						
/H.K./	BA	WALDMANN et al., <i>Ann. Intern. Med.</i> , 116(2), 148-160 (1992)						

Examiner Signature	/Hemant Khanna/	Date Considered	04/24/2007
--------------------	-----------------	-----------------	------------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

* An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

JAN 25 2006

(Use as many sheets as necessary)

Complete if Known

Application Number	10/505,239
Filing Date	October 12, 2004
First Named Inventor	TARASOVA et al.
Group Art Unit	1654
Examiner Name	Jennifer L. HARLE HEMANT KHANNA
Attorney Docket Number	229694

[illegible][illegible][illegible]

Examiner Signature	/Hemant Khanna/	Date Considered	04/24/2007
--------------------	-----------------	-----------------	------------

- * An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).